Tezepelumab-ekko (Tezspire) is the first and only biologic agent approved by the FDA for severe asthma that is not limited to a specific asthma phenotype. 

Biologic agents have ben a true god-send in terms of helping patients with severe asthma.  The underlying cause for asthma is inflammation.  But the cause of the inflammation varies from patient to patient.  This variability is where the term phenotype comes into play.  Identifying the specific immune mechanism that instigates the inflammation and thus the asthma has proven extremely useful.  There are already a number of biologic agents that are extremely effective but to date they tend to target a single specific inflammatory mediator.  In most cases that is all that is required.  However, asthmatic inflammation can sometimes be multifactorial or what is referred to as a cascade effect.  Think of dominoes falling into one another.  This is where Tezepelumab-ekko can have utility.

Of course, every coin has two sides.  With its broader impact on immune modulators there is also a potential for reducing desirable immune function.  If a patient had a helminth infection this could worsen.  Also, live vaccines must be avoided.